The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Mon, 04th May 2020 14:35

(Alliance News) - Open Orphan PLC on Monday announced that Chief Executive Trevor Phillips will be standing down and said it has signed a new contract with a US biotechnology.

Shares in the pharmaceutical services firm were up 10% at 9.90 pence in London in afternoon trading.

Philips will stay in his role until June end but has departed the board with immediate effects. He joined hVIVO at the end of 2018 and led hVIVO's merger with Open Orphan. Executive Chair Cathal Friel will lead Open Orphan.

The new contract is for Open Orphan to provide a human challenge study in respiratory syncytial virus, a highly contagious viral disease and among the most common causes of pneumonia and bronchiolitis. Challenge studies purposefully expose healthy volunteers to an infectious disease.

The biotechnology company's name was not disclosed, though Open Orphan expects to receive around GBP3.5 million of revenue in 2020 from the study.

Open Orphan acquired Venn Life Sciences Holdings PLC in January, the same month its completed its merger with hVIVO PLC. The study will use the clinical research organisation services of hVIVO and Venn and will take place at hVIVO's London-based quarantine unit in the third quarter of 2020.

Friel said: "Firstly, I would like to thank Trevor for his help merging Open Orphan and hVIVO. Trevor had previously successfully right sized and focused hVIVO and our refreshed management team is now focused on delivering growth at a very exciting time for the company.

"The signing of this new GBP3.5 million contract with a US biotechnology company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts. Open Orphan will be utilising its complementary in-house [clinical research organisation] services of hVIVO and Venn to deliver this contract. This contract demonstrates the Open Orphan and hVivo group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reduce costs."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2020 10:51

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Read more
16 Jan 2020 18:15

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Read more
14 Jan 2020 16:10

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Read more
6 Jan 2020 17:29

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 11:49

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 10:55

Open Orphan inks three-year contract with mystery European firm

(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.

Read more
31 Dec 2019 09:46

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Read more
31 Dec 2019 06:31

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Dec 2019 12:54

Open Orphan signs deal with US biopharmaceutical firm SFA

(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.

Read more
18 Dec 2019 12:29

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Read more
9 Dec 2019 14:36

Open Orphan agrees acquisition of hVIVO at 34% premium

(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.

Read more
9 Dec 2019 11:23

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Read more
25 Nov 2019 14:57

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Read more
18 Nov 2019 10:35

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Read more
18 Nov 2019 09:58

Open Orphan signs pharmacology trial contract with Carna

(Sharecast News) - Rare and orphan drug consulting services provider Open Orphan announced the signing of a contract with Carna Bioscience for a first-in-human clinical pharmacology trial, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.